Evidence map›Paper›PMID 35582130›Full record

ArticleWorld journal of gastroenterology2022

Liquid biopsy in colorectal cancer: No longer young, but not yet old.

Giandomenico Roviello, Daniele Lavacchi, Lorenzo Antonuzzo, Martina Catalano, Enrico Mini

Open access · hybridAbstract readEditorial
In one paragraph

Article in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Firenze 50139, Italy. giandomenico.roviello@unifi.it.
Daniele LavacchiClinical Oncology Unit, AOU Careggi, Firenze 50134, Italy.
Lorenzo AntonuzzoDepartment of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.
Martina CatalanoSchool of Human Health Sciences, University of Florence, Florence 50134, Italy.
Enrico MiniDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Firenze 50139, Italy.
University of Florence · ITKurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most prevalent cancers and the second leading cause of cancer-related deaths worldwide. The treatment strategy employed in CRC patients is becoming highly dependent on molecular characteristics present at diagnosis and during treatment. Liquid biopsy is an emerging field in the management of this cancer, and its relevance as a potential diagnostic, prognostic, monitoring, and therapeutic tool makes it a viable strategy in the clinical management of CRC patients. Liquid biopsy also has certain limitations, but these limitations seem to be at the reach of near-future technological development. In this letter, we focus on the clinical perspectives of liquid biopsy in CRC with particular regard to the various biomarkers recently identified that have been shown to be potentially useful in multiple aspects of early stage or metastatic CRC.

Indexed as

Colorectal NeoplasmsBiomarkers, TumorHumansLiquid BiopsyPrognosisBiomarkers, TumorCirculating tumor DNAColorectal cancerDiagnosisLiquid biopsyPrognosisTargeted therapy

Identifiers

PMID35582130
PMCPMC9048462
OpenAlexW4223922942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.